quinoxalines has been researched along with Cardiomyopathy, Chagas in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alves-Filho, JC; Baron, M; Cardozo, LE; Chevillard, C; Cunha, FQ; Cunha, TM; Cunha-Neto, E; Davoli-Ferreira, M; Dias, FC; Figueiredo, F; Frade, AF; Gava, FN; Hirsch, E; Lopes, CD; Lyroni, K; Medina, TS; Nakaya, HI; Sesti-Costa, R; Silva, GK; Silva, JS; Silva, MC; Tsatsanis, C | 1 |
1 other study(ies) available for quinoxalines and Cardiomyopathy, Chagas
Article | Year |
---|---|
Canonical PI3Kγ signaling in myeloid cells restricts Trypanosoma cruzi infection and dampens chagasic myocarditis.
Topics: Adult; Animals; Biopsy; Cell Line; Chagas Cardiomyopathy; Class Ib Phosphatidylinositol 3-Kinase; Disease Models, Animal; Female; Heart; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Myeloid Cells; Myocardium; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Signal Transduction; Thiazolidinediones; Trypanosoma cruzi; Up-Regulation | 2018 |